Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors

N. B. O'Mara; W. B. Zimmerman; I. Joffe; R. B. Devereux; M. Packer; M. Gheorghiade; J. B. Young

doi:10.1056/NEJM199312093292417

Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors

N. B. O'Mara, W. B. Zimmerman, I. Joffe, R. B. Devereux, M. Packer, M. Gheorghiade, J. B. Young

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

25 Scopus citations

Abstract

To the Editor: We wish to highlight a shortcoming of the study by Packer et al. (July 1 issue)¹ regarding the withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme (ACE) inhibitors. The authors state that during the single-blind run-in period the doses of ACE inhibitor were increased “so that a daily dose of at least 25 mg of captopril or 5 mg of enalapril was achieved.” This dosage level was to provide “optimal clinical benefits.” During the study, patients received an average daily dose of 73 mg of captopril or 13 mg of enalapril in the…

Original language	English (US)
Pages (from-to)	1819-1820
Number of pages	2
Journal	New England Journal of Medicine
Volume	329
Issue number	24
DOIs	https://doi.org/10.1056/NEJM199312093292417
State	Published - Dec 9 1993

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM199312093292417

Cite this

@article{acf04ca5fd2a442baa36fcd52a45896d,

title = "Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors",

abstract = "To the Editor: We wish to highlight a shortcoming of the study by Packer et al. (July 1 issue)1 regarding the withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme (ACE) inhibitors. The authors state that during the single-blind run-in period the doses of ACE inhibitor were increased “so that a daily dose of at least 25 mg of captopril or 5 mg of enalapril was achieved.” This dosage level was to provide “optimal clinical benefits.” During the study, patients received an average daily dose of 73 mg of captopril or 13 mg of enalapril in the…",

author = "O'Mara, {N. B.} and Zimmerman, {W. B.} and I. Joffe and Devereux, {R. B.} and M. Packer and M. Gheorghiade and Young, {J. B.}",

year = "1993",

month = dec,

day = "9",

doi = "10.1056/NEJM199312093292417",

language = "English (US)",

volume = "329",

pages = "1819--1820",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors

AU - O'Mara, N. B.

AU - Zimmerman, W. B.

AU - Joffe, I.

AU - Devereux, R. B.

AU - Packer, M.

AU - Gheorghiade, M.

AU - Young, J. B.

PY - 1993/12/9

Y1 - 1993/12/9

N2 - To the Editor: We wish to highlight a shortcoming of the study by Packer et al. (July 1 issue)1 regarding the withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme (ACE) inhibitors. The authors state that during the single-blind run-in period the doses of ACE inhibitor were increased “so that a daily dose of at least 25 mg of captopril or 5 mg of enalapril was achieved.” This dosage level was to provide “optimal clinical benefits.” During the study, patients received an average daily dose of 73 mg of captopril or 13 mg of enalapril in the…

AB - To the Editor: We wish to highlight a shortcoming of the study by Packer et al. (July 1 issue)1 regarding the withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme (ACE) inhibitors. The authors state that during the single-blind run-in period the doses of ACE inhibitor were increased “so that a daily dose of at least 25 mg of captopril or 5 mg of enalapril was achieved.” This dosage level was to provide “optimal clinical benefits.” During the study, patients received an average daily dose of 73 mg of captopril or 13 mg of enalapril in the…

UR - http://www.scopus.com/inward/record.url?scp=0027504386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027504386&partnerID=8YFLogxK

U2 - 10.1056/NEJM199312093292417

DO - 10.1056/NEJM199312093292417

M3 - Letter

C2 - 8232501

AN - SCOPUS:0027504386

SN - 0028-4793

VL - 329

SP - 1819

EP - 1820

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -

Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this